WO1999038888A3 - Inhibiteurs peptidiques de l'activite de la serine protease associee a la proteine ns53 de vhc, leurs utilisations correspondantes et leur procede de production - Google Patents

Inhibiteurs peptidiques de l'activite de la serine protease associee a la proteine ns53 de vhc, leurs utilisations correspondantes et leur procede de production Download PDF

Info

Publication number
WO1999038888A3
WO1999038888A3 PCT/IT1999/000022 IT9900022W WO9938888A3 WO 1999038888 A3 WO1999038888 A3 WO 1999038888A3 IT 9900022 W IT9900022 W IT 9900022W WO 9938888 A3 WO9938888 A3 WO 9938888A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein
production
hcv
protease activity
activity associated
Prior art date
Application number
PCT/IT1999/000022
Other languages
English (en)
Other versions
WO1999038888A2 (fr
Inventor
Antonello Pessi
Christian Steinkuehler
Francesco Raffaele De
Original Assignee
Angeletti P Ist Richerche Bio
Antonello Pessi
Christian Steinkuehler
Francesco Raffaele De
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angeletti P Ist Richerche Bio, Antonello Pessi, Christian Steinkuehler, Francesco Raffaele De filed Critical Angeletti P Ist Richerche Bio
Priority to JP2000529354A priority Critical patent/JP2002509075A/ja
Priority to EP99905173A priority patent/EP1053249A2/fr
Priority to CA002319306A priority patent/CA2319306A1/fr
Priority to AU25450/99A priority patent/AU2545099A/en
Publication of WO1999038888A2 publication Critical patent/WO1999038888A2/fr
Publication of WO1999038888A3 publication Critical patent/WO1999038888A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne des peptides capables d'inhiber l'activité de la sérine protéase associée à la protéine NS53 du virus de l'hépatite C (VHC), leurs utilisations et leur procédé de production consistant à effectuer la protéolyse de polypeptides contenant au moins une séquence sélectionnée parmi les sites de jonction NS3/NS4A, NS4A/NS4B, NS4B/NS5A et/ou NS5A/NS5B de la polyprotéine du VHC.
PCT/IT1999/000022 1998-02-02 1999-02-02 Inhibiteurs peptidiques de l'activite de la serine protease associee a la proteine ns53 de vhc, leurs utilisations correspondantes et leur procede de production WO1999038888A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2000529354A JP2002509075A (ja) 1998-02-02 1999-02-02 Ｈｃｖのｎｓ３タンパク質に関連したセリンプロテアーゼ活性のペプチド阻害剤、関連する使用およびその製造方法
EP99905173A EP1053249A2 (fr) 1998-02-02 1999-02-02 Inhibiteurs peptidiques de l'activite de la serine protease associee a la proteine ns53 de vhc, leurs utilisations correspondantes et leur procede de production
CA002319306A CA2319306A1 (fr) 1998-02-02 1999-02-02 Inhibiteurs peptidiques de l'activite de la serine protease associee a la proteine ns53 de vhc, leurs utilisations correspondantes et leur procede de production
AU25450/99A AU2545099A (en) 1998-02-02 1999-02-02 Peptide inhibitors of the serine protease activity associated to the ns3 proteinof hcv, relevant uses and process of production

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITRM98A000061 1998-02-02
IT98RM000061A IT1299134B1 (it) 1998-02-02 1998-02-02 Procedimento per la produzione di peptidi con proprieta' inibitrici della proteasi ns3 del virus hcv, peptidi cosi' ottenibili e peptidi

Publications (2)

Publication Number Publication Date
WO1999038888A2 WO1999038888A2 (fr) 1999-08-05
WO1999038888A3 true WO1999038888A3 (fr) 1999-10-07

Family

ID=11405519

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IT1999/000022 WO1999038888A2 (fr) 1998-02-02 1999-02-02 Inhibiteurs peptidiques de l'activite de la serine protease associee a la proteine ns53 de vhc, leurs utilisations correspondantes et leur procede de production

Country Status (6)

Country Link
EP (1) EP1053249A2 (fr)
JP (1) JP2002509075A (fr)
AU (1) AU2545099A (fr)
CA (1) CA2319306A1 (fr)
IT (1) IT1299134B1 (fr)
WO (1) WO1999038888A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8871904B2 (en) 2005-08-19 2014-10-28 Vertex Pharmaceuticals Incorporated Processes and intermediates

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
GB9925955D0 (en) 1999-11-02 1999-12-29 Angeletti P Ist Richerche Bio Hcv n33 protease inhibitors
MY134070A (en) 2001-01-22 2007-11-30 Isis Pharmaceuticals Inc Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
US7119072B2 (en) 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
US6642204B2 (en) 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US7091184B2 (en) 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
NZ561851A (en) 2002-04-11 2009-05-31 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis C virus NS3 - NS4 protease
WO2004032827A2 (fr) 2002-05-20 2004-04-22 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hepatite c
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
ES2315568T3 (es) 2002-05-20 2009-04-01 Bristol-Myers Squibb Company Inhibidores del virus de la hepatitis c basados en cicloalquilo p1' sustituido.
ATE481106T1 (de) 2002-05-20 2010-10-15 Bristol Myers Squibb Co Heterocyclische sulfonamid-hepatitis-c-virus- hemmer
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
DK1654261T3 (da) 2003-05-21 2008-01-14 Boehringer Ingelheim Int Hepatitis C-inhibitorforbindelser
AR045596A1 (es) 2003-09-05 2005-11-02 Vertex Pharma Inhibidores de proteasas de serina en particular proteasa ns3-ns4a del vhc
WO2005028501A1 (fr) 2003-09-22 2005-03-31 Boehringer Ingelheim International Gmbh Peptides macrocycliques actifs contre le virus de l'hepatite c
KR20060130027A (ko) 2003-10-10 2006-12-18 버텍스 파마슈티칼스 인코포레이티드 세린 프로테아제, 특히 ｈｃｖ ｎｓ3-ｎｓ4ａ 프로테아제의억제제
BRPI0415373A (pt) 2003-10-14 2006-12-12 Intermune Inc ácidos carboxìlicos macrocìclicos e acilsulfonamidas como inibidores de replicação de hcv
WO2005043118A2 (fr) 2003-10-27 2005-05-12 Vertex Pharmaceuticals Incorporated Methode de decouverte de medicament
EP1944042A1 (fr) 2003-10-27 2008-07-16 Vertex Pharmceuticals Incorporated Combinaisons pour le traitement HCV
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7309708B2 (en) 2003-11-20 2007-12-18 Birstol-Myers Squibb Company Hepatitis C virus inhibitors
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2005070955A1 (fr) 2004-01-21 2005-08-04 Boehringer Ingelheim International Gmbh Peptides macrocycliques actifs contre le virus de l'hepatite c
US7683033B2 (en) 2004-02-04 2010-03-23 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
AU2005254057B2 (en) 2004-06-15 2011-02-17 Isis Pharmaceuticals, Inc. C-purine nucleoside analogs as inhibitors of RNA-dependent RNA viral polymerase
WO2006012078A2 (fr) 2004-06-24 2006-02-02 Merck & Co., Inc. Phosphoramidates d'aryle nucleosidiques pour le traitement d'infection virale arn dependante de l'arn
ATE512971T1 (de) 2004-07-20 2011-07-15 Boehringer Ingelheim Int Peptidanaloga als hepatitis c-hemmer
UY29016A1 (es) 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
ATE514708T1 (de) * 2004-08-27 2011-07-15 Chrontech Pharma Ab Transgene mausmodelle des hepatitis c virus (hcv) sowie identifizierung von hcv therapeutika
WO2006109196A2 (fr) * 2005-02-04 2006-10-19 Tripep Ab Modeles de souris transgeniques du virus de l'hepatite c (vhc) et identification des therapies pour le vhc
US7470664B2 (en) 2005-07-20 2008-12-30 Merck & Co., Inc. HCV NS3 protease inhibitors
AU2006276246B2 (en) 2005-07-25 2012-09-27 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis C virus replication
WO2007016441A1 (fr) 2005-08-01 2007-02-08 Merck & Co., Inc. Peptides macrocycliques en tant qu’inhibiteurs de la protéase ns3 du vhc
US20070105781A1 (en) 2005-08-02 2007-05-10 Steve Lyons Inhibitors of serine proteases
EP1915054A4 (fr) 2005-08-09 2010-09-01 Merck Sharp & Dohme Derives d'acetaux cycliques de ribonucleosides pour traiter une infection virale d'arn arn dependante
SI2194043T1 (sl) 2005-08-19 2014-04-30 Vertex Pharmaceuticals Incorporated Postopki
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
CN101415705B (zh) 2005-10-11 2011-10-26 因特蒙公司 抑制丙型肝炎病毒复制的化合物和方法
EP2392590A3 (fr) 2005-11-11 2012-03-14 Vertex Pharmaceuticals Incorporated Variantes du virus de l'hépatite C
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
GB0609492D0 (en) 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
GB0612423D0 (en) 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
EP1886685A1 (fr) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes, utilisations et compositions pour la modulation de la réplication du HCV par activation ou inhibition du récepteur farnesoid X
JP2010507656A (ja) 2006-10-24 2010-03-11 メルク エンド カムパニー インコーポレーテッド Ｈｃｖｎｓ３プロテアーゼ阻害剤
EP2079480B1 (fr) 2006-10-24 2013-06-05 Merck Sharp & Dohme Corp. Inhibiteurs de la protéase ns3 du hcv
WO2008051475A2 (fr) 2006-10-24 2008-05-02 Merck & Co., Inc. Inhibiteurs de la protéase ns3 du vhc
ES2444575T3 (es) 2006-10-27 2014-02-25 Merck Sharp & Dohme Corp. Inhibidores de la proteasa NS3 del VHC
KR101615500B1 (ko) 2006-10-27 2016-04-27 머크 샤프 앤드 돔 코포레이션 Ｈｃｖ ｎｓ3 프로테아제 억제제
GB0625345D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
JP2010513450A (ja) 2006-12-20 2010-04-30 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー 抗ウイルス性インドール
CN101815533A (zh) 2007-05-04 2010-08-25 弗特克斯药品有限公司 用于治疗hcv感染的组合治疗
AP2009005073A0 (en) 2007-06-29 2009-12-31 Gilead Sciences Inc Antiviral compounds
EA025794B1 (ru) 2007-06-29 2017-01-30 Джилид Сайэнс, Инк. Противовирусные соединения
EP2178885A1 (fr) 2007-07-17 2010-04-28 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Dérivés macrocycliques d'indole pour le traitement des infections d'hépatite c
CN101754974B (zh) 2007-07-19 2016-02-03 Msd意大利有限公司 作为抗病毒剂的大环化合物
WO2009039989A1 (fr) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Utilisation du peptide gly-arg-gly-asp-asn-pro en tant qu'agent thérapeutique
GB0718575D0 (en) 2007-09-24 2007-10-31 Angeletti P Ist Richerche Bio Nucleoside derivatives as inhibitors of viral polymerases
WO2009134624A1 (fr) 2008-04-28 2009-11-05 Merck & Co., Inc. Inhibiteurs de la protéase hcv ns3
RS53420B (en) 2008-07-22 2014-12-31 Msd Italia S.R.L. MACROCYCLIC COMPOUNDS OF HINOXALINE, WHICH IS AN INHIBITOR OF HCV NS3 PROTEASES WITH OTHER HCV AGENTS
WO2010082050A1 (fr) 2009-01-16 2010-07-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Composés benzoxazocines substitués 7-aminoalkyle macrocycycliques destinés au traitement des infections par hépatite c
GB0900914D0 (en) 2009-01-20 2009-03-04 Angeletti P Ist Richerche Bio Antiviral agents
US8828930B2 (en) 2009-07-30 2014-09-09 Merck Sharp & Dohme Corp. Hepatitis C virus NS3 protease inhibitors
WO2012107589A1 (fr) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques pour le traitement et la prévention des infections à vhc
EP2780026B1 (fr) 2011-11-15 2019-10-23 Merck Sharp & Dohme Corp. Inhibiteurs de la protéase ns3 du vhc
WO2013106344A1 (fr) 2012-01-12 2013-07-18 Ligand Pharmaceuticals, Inc. Nucléosides 2'-c-méthyl comprenant un diester de phosphate cyclique de 1,3-propanediol (2-oxo-[1,3,2]-dioxaphosphorinane à la position 5'
WO2014121417A1 (fr) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Composés hétérocycliques tétracycliques et leurs procédés d'utilisation pour le traitement de l'hépatite c
WO2014121418A1 (fr) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Composés hétérocycliques tétracycliques et leurs méthodes d'utilisation pour le traitement de l'hépatite c

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997008304A2 (fr) * 1995-08-22 1997-03-06 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Methode de production, de purification et d'analyse de polypeptides par l'activite proteolytique de la vhc ns3 protease
WO1997043310A1 (fr) * 1996-05-10 1997-11-20 Schering Corporation Inhibiteurs synthetiques de la protease ns3 du virus de l'hepatite c
WO1999007733A2 (fr) * 1997-08-11 1999-02-18 Boehringer Ingelheim (Canada) Ltd. Peptides inhibiteurs de l'hepatite c

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997008304A2 (fr) * 1995-08-22 1997-03-06 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Methode de production, de purification et d'analyse de polypeptides par l'activite proteolytique de la vhc ns3 protease
WO1997043310A1 (fr) * 1996-05-10 1997-11-20 Schering Corporation Inhibiteurs synthetiques de la protease ns3 du virus de l'hepatite c
WO1999007733A2 (fr) * 1997-08-11 1999-02-18 Boehringer Ingelheim (Canada) Ltd. Peptides inhibiteurs de l'hepatite c

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GRAKOUI E.A.: "Characterization of the HCV-encoded serine proteinase", J.VIROL., vol. 67, no. 5, 1993, pages 2832 - 2843, XP002111520 *
INGALLINELLA E A: "Potent peptide inhibitors of human HCV NS3 protease are obtained by optimizing the cleavage products", BIOCHEMISTRY, vol. 37, 23 June 1998 (1998-06-23), pages 8906 - 8914, XP002086572, ISSN: 0006-2960 *
LANDRO E.A.: "Mechanistic role of an NS4A cofactor with the truncated NS3 protease of HCV", BIOCHEMISTRY, vol. 36, no. 31, 1997, EASTON, PA US, pages 9340 - 9348, XP002111518 *
LLINAS-BRUNET M ET AL: "Peptide-based inhibitors of the hepatitis C virus serine protease", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 8, no. 13, 7 July 1998 (1998-07-07), pages 1713-1718, XP004137115, ISSN: 0960-894X *
TOKITA E.A.: "HCV variants from Jakarta, Indonesia classifiable into novel genotypes in the second (2e and 2f) and eleventh (11a) genetic groups.", J.GEN.VIROL., vol. 77, 1996, pages 293 - 301, XP002111519 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8871904B2 (en) 2005-08-19 2014-10-28 Vertex Pharmaceuticals Incorporated Processes and intermediates

Also Published As

Publication number Publication date
WO1999038888A2 (fr) 1999-08-05
IT1299134B1 (it) 2000-02-29
JP2002509075A (ja) 2002-03-26
CA2319306A1 (fr) 1999-08-05
ITRM980061A0 (it) 1998-02-02
ITRM980061A1 (it) 1999-08-02
AU2545099A (en) 1999-08-16
EP1053249A2 (fr) 2000-11-22

Similar Documents

Publication Publication Date Title
WO1999038888A3 (fr) Inhibiteurs peptidiques de l'activite de la serine protease associee a la proteine ns53 de vhc, leurs utilisations correspondantes et leur procede de production
DE122012000004I1 (de) Peptide als inhibitoren der NS3-Serinprotease des hepatitis c virus.
ATE277945T1 (de) Makrozyklische peptide als hepatitis c virus ns3 protease inhibitore
Llinas-Brunet et al. Peptide-based inhibitors of the hepatitis C virus serine protease
NO991832L (no) Inhibitorer for serin-proteaser, spesielt hepatitt - C - virus NS3-protease
NO20030271D0 (no) Nye peptider som NS3-serinproteaseinhibitorer for hepatitt C- virus
ATE430166T1 (de) Diarylrest entfassende peptide als inhibitoren des ns-3 serinproteases von hepatitis c virus
Butkiewicz et al. Enhancement of hepatitis C virus NS3 proteinase activity by association with NS4A-specific synthetic peptides: identification of sequence and critical residues of NS4A for the cofactor activity
AU1416099A (en) Single-chain recombinant complexes of hepatitis c virus ns3 protease and ns4a cofactor peptide
IL176237A0 (en) Inhibitors of hepatitis c virus ns3/ns4a serine protease
DE60332814D1 (de) Peptide als hemmer der serinprotease des hepatitis c virus
HUP0302957A2 (hu) Hepatitis C vírus alkil- és aril-alanin P2 csoportokat tartalmazó makrociklusos NS-3 szerin proteáz inhibitorai
WO2004111082A3 (fr) Composition comprenant la polyproteine ns3/ns4 et le polypeptide ns5b du vhc, vecteurs d'expression incluant les sequences nucleiques correspondantes et leur utilisation en therapeutique
HK1081196A1 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
NO20024797D0 (no) Makrosykliske NS3-serinproteaseinhibitorer for hepatitt C- virus, som omfatter N-sykliske P2-rester
ATE423127T1 (de) Peptidinhibitoren der ns3-protease des hepatoitis c virus
HK1038573A1 (en) Method to identify agents active against hcv by using the structure coordinates of hepatitis c virus protease
Schaschke Miraziridine A: natures blueprint towards protease class-spanning inhibitors
Kakiuchi et al. Non-peptide inhibitors of HCV serine proteinase
SI0932617T1 (en) Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
ATE542140T1 (de) Nichtstrukturelle hcv-proteinmutanten und verwendungsmöglichkeiten dafür
Fischmann et al. Peptidic inhibitors of the hepatitis C virus serine protease within non-structural protein 3
KR980002263A (ko) C형 간염 바이러스의 프로테아제의 활성을 측정할 수 있는 c형 간염 대체 바이러스, 그 재조합 유전자 및 그 용도
WO2000001718A3 (fr) Domaine catalytique ns4a et ns3 de l'hepatite c
Murtuja et al. A Critical Observation on the Design and Development of Reported Peptide Inhibitors of DENV NS2B-NS3 Protease in the Last Two Decades

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA CN IL JP KR MX NO NZ US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA CN IL JP KR MX NO NZ US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2319306

Country of ref document: CA

Ref country code: CA

Ref document number: 2319306

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 09601516

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 25450/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999905173

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999905173

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999905173

Country of ref document: EP